Carol Fabian, MD
16
1
1
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
18.8%
3 terminated/withdrawn out of 16 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
58%
7 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
Role: lead
Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers
Role: lead
High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women
Role: lead
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Role: lead
Study of Breast Cancer Prevention by Letrozole in High Risk Women
Role: lead
Protocol to Examine Methylation of Tumor Suppression Genes in Women at High Risk of Developing Breast Cancer
Role: lead
Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women
Role: lead
Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy
Role: lead
Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms
Role: lead
Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
Role: lead
Breast Cancer Risk Biomarkers in Postmenopausal Women
Role: lead
Protocol for Women at Increased Risk of Developing Breast Cancer
Role: lead
Breast Cancer Risk Biomarkers in Premenopausal Women
Role: lead
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
Role: lead
Protocol for Women at Increased Risk of Developing Breast Cancer
Role: lead
Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
Role: lead
All 16 trials loaded